Written by Keen Meds · Reviewed by Licensed Clinical Providers · March 1, 2026
Key Insight: Transdermal testosterone produces relatively stable, consistent diurnal testosterone levels throughout the day -- unlike intramuscular injections, which create supraphysiological peaks within days of injection followed by subtherapeutic troughs before the next dose.
When choosing a testosterone replacement therapy formulation, pharmacokinetics matter. Pharmacokinetics is the study of how a drug is absorbed, distributed, and eliminated by the body. For testosterone specifically, the pharmacokinetic profile of your delivery method determines whether you spend most of your time with testosterone at a stable therapeutic level or oscillating between peaks that are too high and troughs that are too low. Transdermal delivery -- applying testosterone directly to the skin -- produces a fundamentally different pharmacokinetic profile than injections, and that difference has real clinical implications. This article explains the biology of how testosterone moves through skin into systemic circulation, what factors affect absorption, and why the stable pharmacokinetic profile of transdermal delivery is clinically advantageous.
The Anatomy of Transdermal Absorption
To understand how transdermal testosterone works, it helps to understand the structure of the skin.
The outermost layer of skin is the stratum corneum -- a tough, lipid-rich barrier composed of flattened, dead keratinocyte cells held together by lipid bilayers. The stratum corneum evolved primarily as a protective barrier against water loss and environmental intrusion. It is not designed to let molecules through easily. The thickness of the stratum corneum, its lipid composition, and its hydration level all affect how readily any given molecule can penetrate it.
Below the stratum corneum lies the viable epidermis, then the dermis -- the thicker layer containing blood vessels, nerve endings, hair follicles, and sweat glands. Testosterone must pass through the stratum corneum barrier and into the viable epidermis and dermis, where it can enter dermal capillaries and reach systemic circulation.
Testosterone is a lipophilic (fat-loving) steroid molecule, which gives it an inherent advantage in penetrating the lipid-rich stratum corneum compared to hydrophilic (water-loving) drugs. This natural affinity for lipid environments is the reason steroids in general can be delivered transdermally, while many other drug classes cannot.
Pharmaceutical transdermal formulations -- gels, sprays, creams -- include vehicle systems (carriers such as ethanol, propylene glycol, and other excipients) that further enhance penetration. These vehicles disrupt or temporarily modify the stratum corneum's lipid barrier, increasing testosterone's passage rate. The specific vehicle composition differs between formulations and is one of the factors that influences the dose-per-application relationship.
The Stratum Corneum as a Reservoir
One of the most important pharmacokinetic properties of transdermal testosterone delivery is the reservoir effect. Rather than releasing testosterone immediately into the bloodstream upon application, the testosterone first accumulates within the stratum corneum and viable epidermis, forming a reservoir. This reservoir then releases testosterone gradually over the following 24 hours as the concentration gradient drives diffusion into deeper tissue and capillaries.
This reservoir effect is the fundamental reason why transdermal testosterone produces more stable blood levels than injections. The skin acts as a natural depot that smooths out the delivery curve, releasing testosterone steadily rather than all at once.
With daily application to the same area, a steady-state reservoir builds within the stratum corneum over the first 24 to 72 hours. After this equilibration period, testosterone enters systemic circulation at a relatively consistent rate day to day, maintaining blood levels in the mid-physiological range without large swings.
Comparing Pharmacokinetic Profiles: Transdermal vs. Injection
The pharmacokinetic contrast between daily transdermal testosterone and biweekly intramuscular injections is clinically significant.
A standard intramuscular injection of testosterone cypionate or testosterone enanthate (typically dosed every 7 to 14 days) produces a well-characterized biphasic pattern. In the first 24 to 72 hours after injection, testosterone levels rise rapidly as the depot releases drug into systemic circulation. Levels typically peak at 2 to 3 times the upper normal physiological range -- reaching values of 1,200 to 2,000 ng/dL or higher -- before declining as the drug is metabolized and cleared. By day 10 to 14, depending on the ester used and the injection interval, testosterone may fall below the therapeutic threshold, leaving men with subtherapeutic levels in the days before their next injection.
This peak-trough pattern has consequences. Supraphysiological peaks drive more erythropoiesis than physiological levels do -- the elevated testosterone stimulates more erythropoietin production, raising hematocrit more aggressively than daily transdermal delivery. Supraphysiological peaks are also associated with greater conversion to estradiol via aromatase, potentially causing estrogen-related side effects like water retention and mood changes. And the subjective "trough effect" -- declining energy, mood, and libido in the days before the next injection -- is a commonly reported experience among men on biweekly injection protocols.
Daily transdermal testosterone delivers a different curve. Testosterone rises modestly from the pre-application baseline each morning after application and then follows the natural diurnal decline through the day, approximately mirroring the body's normal rhythm of higher morning testosterone declining across the afternoon. The levels remain within the physiological range -- typically between 400 and 700 ng/dL at steady state -- without supraphysiological peaks or subtherapeutic troughs.
Application Variables: What Affects Absorption Rate
Not all skin is equal for testosterone absorption. Several practical variables affect how much testosterone reaches systemic circulation from a given dose.
Application site is significant. Skin thickness and vascularity vary across body sites. Thinner skin with closer underlying vasculature absorbs testosterone more readily. The inner arm, upper arm, inner thigh, and abdomen are typical application sites. The scrotum absorbs testosterone particularly efficiently due to extremely thin, highly vascular skin -- some formulations are specifically approved for scrotal application for this reason.
Temperature affects absorption. Heat increases skin blood flow and enhances drug diffusion. Applying testosterone before a hot shower or in a warm environment increases absorption compared to cool conditions. Conversely, exercising immediately after application can increase local temperature and accelerate absorption variably.
Skin hydration and condition matter. Clean, dry skin without applied lotions or sunscreen provides an optimal surface. Other skin products applied to the same site can form a layer that interferes with the testosterone vehicle's penetration.
Individual variation in stratum corneum thickness and lipid composition creates meaningful interpatient variability. Two men applying the same dose from the same formulation will not necessarily achieve identical serum testosterone levels. This is one reason why monitoring testosterone levels at 3 months after starting transdermal therapy is important -- confirming that the individual has reached the therapeutic range, and adjusting dose if necessary.
Spray vs. Gel: Clinical Differences
Testosterone spray and testosterone gel share the same fundamental delivery principle -- transdermal absorption through vehicle-enhanced penetration -- but differ in several practical ways.
Spray delivery typically delivers a more precisely controlled dose per actuation (pump press) than gel applied by hand. The spray format reduces the opportunity for handling errors, such as under- or over-measuring a gel dose. Spray formulations also generally dry faster, reducing the window during which accidental transfer to a partner or child could occur through skin contact.
Transfer risk is a general concern with all transdermal testosterone -- it is highest when someone touches treated skin before the vehicle has fully dried and absorbed. Both gel and spray formulations require covering the treated site or washing hands after application to minimize transfer risk.
Frequently Asked Questions
How long does it take for transdermal testosterone to reach steady-state levels in blood?
Testosterone blood levels begin rising within hours of the first application. Steady-state serum levels are typically achieved within 24 to 72 hours of initiating daily application, as the stratum corneum reservoir equilibrates. Full assessment of your actual therapeutic testosterone level should be done approximately 2 to 4 weeks after starting therapy and confirmed at the standard 3-month monitoring check.
Does my skin type affect how well transdermal testosterone works?
Yes, to a degree. Skin thickness, hydration, and lipid composition affect absorption rate. Men with naturally thicker skin (common in older men and men of some ethnic backgrounds) may absorb slightly less per dose. This is one reason why monitoring and dose adjustment are important -- the right dose is the one that achieves a therapeutic serum level for you specifically, not a standardized amount.
Is transdermal testosterone safer than injections?
Neither form is categorically safer, but they carry different risk profiles. Transdermal testosterone is associated with lower rates of polycythemia (elevated hematocrit) than injectable testosterone because it does not produce the same supraphysiological peaks that drive erythropoiesis. Injections may be preferred in some clinical situations for compliance reasons. The best formulation for a given patient depends on their clinical needs, risk factors, and preferences -- a conversation for a licensed clinical provider.
Can testosterone spray be transferred to a partner or child?
Yes, transfer is possible if a partner or child contacts untreated skin with residual testosterone before it fully absorbs and dries. To minimize risk, apply spray to areas that are easily covered by clothing, allow the application site to dry completely before contact, wash hands after application, and cover the site with clothing when around others. Transfer risk is lower with spray than with gel due to faster drying time.
What This Means for Your Treatment Decisions
The pharmacokinetic advantage of transdermal testosterone -- stable daily levels within the physiological range, lower polycythemia risk compared to injections, and preserved natural diurnal rhythm -- makes it a clinically well-supported delivery method for men with confirmed hypogonadism who want consistent, manageable testosterone therapy.
Keen Meds connects you with licensed clinical providers for a telehealth evaluation and lab review. If your testosterone is clinically low, you may qualify for Testosterone Spray Rx.
